| Guntinas-Lichius, Orlando |
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) |
|
|
| Recruiting | 3 | 510 | Europe, Canada, Japan, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 10/26 | 02/27 | | |
| Recruiting | 3 | 500 | Europe, Japan, US, RoW | JNJ-90301900 (NBTXR3), Functionalized hafnium oxide nanoparticles, NBTXR3, Cetuximab, Erbitux, Radiation Therapy | Johnson & Johnson Enterprise Innovation Inc., Nanobiotix SA | Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged | 06/26 | 06/27 | | |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
Best Of, NCT02984410: Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma |
|
|
| Recruiting | 3 | 112 | Europe | Intensity-Modulated Radiation Therapy (IMRT), Trans Oral Surgery (TOS) | European Organisation for Research and Treatment of Cancer - EORTC | Oropharyngeal Cancer, Supraglottic Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | 09/25 | 09/29 | | |
PROHEAR, NCT06521190: ACOU085 for Hearing Loss Prevention in Testicular Cancer Patients Receiving Cisplatin |
|
|
| Recruiting | 2 | 40 | Europe | ACOU085 (bimokalner), Placebo | Acousia Therapeutics GmbH | Cisplatin-induced Hearing Loss | 03/25 | 09/25 | | |
| Recruiting | 2 | 140 | Europe | KEYTRUDA®, Pembrolizumab, MK-3475 | University of Leipzig, University of Göttingen, University of Jena, University of Cologne, University of Ulm, University of Regensburg, Wuerzburg University Hospital, Technical University of Munich, Ernst von Bergmann Hospital, Universitätsmedizin Mannheim, University of Kiel | Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III, Laryngeal Squamous Cell Carcinoma Stage IV, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Larynx Stage III, Squamous Cell Carcinoma of the Larynx Stage IV, Laryngeal Squamous Cell Carcinoma, Laryngectomy; Status, Laryngeal Cancer, Laryngeal Neoplasms | 12/28 | 12/30 | | |
| Active, not recruiting | 2 | 240 | Europe | Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA], adjuvant radiochemotherapy | University of Leipzig | HNSCC | 01/25 | 01/25 | | |
NCT05743270: Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN |
|
|
| Withdrawn | 2 | 130 | Europe, US, RoW | RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab | Replimune Inc., Bristol-Myers Squibb | Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 03/26 | 06/26 | | |
| Recruiting | N/A | 4975 | Europe, RoW | RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon | European Organisation for Research and Treatment of Cancer - EORTC | All Tumor Types | 03/26 | 03/26 | | |
